MX352652B - Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico. - Google Patents
Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico.Info
- Publication number
- MX352652B MX352652B MX2014007362A MX2014007362A MX352652B MX 352652 B MX352652 B MX 352652B MX 2014007362 A MX2014007362 A MX 2014007362A MX 2014007362 A MX2014007362 A MX 2014007362A MX 352652 B MX352652 B MX 352652B
- Authority
- MX
- Mexico
- Prior art keywords
- hal
- denotes
- alkyl
- ring
- atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
Abstract
La presente invención proporciona compuestos de la Fórmula (I) como inhibidores de LMP7 para el tratamiento de enfermedades autoinmunes e inflamatorias. En la Fórmula (I), Rb y Rc se seleccionan independientemente entre sí de H o alquilo C1-C6 en donde Rb y Rc pueden enlazarse para formar un anillo de 5 ó 6 miembros que contiene los átomos de oxígeno al que se enlazan; Q representa Ar, Het o cicloalquilo; R1, R2 independientemente entre sí representan H, ORa, Hal, alquilo C1-C6, en donde 1 a 5 átomos de H pueden reemplazarse independientemente por OH o Hal; Y representa CR3R4, de preferencia CH2 o C(CH3)2 R3, R4 independientemente entre sí representan H o alquilo C1-C6 L representa L1 o L2, o alquilo; n es un entero seleccionado de 0 a 3; L1 es Q1-CO-M- en donde Q1 es Ar o Het, de preferencia fenilo, naftilo o piridina, opcionalmente sustituido con 1 a 5 grupos seleccionados independientemente de ORa, Hal, fenilo y alquilo C1-C6, en donde 1 a 5 átomos de H pueden reemplazarse independientemente por OH o Hal; L2 es Q2-M-, en donde Q2 es un sistema bicíclico fusionado que contiene 1 átomo de nitrógeno y 1 a 3 grupos adicionales seleccionados independientemente de O, S, N o CO, y en donde por lo menos uno del anillo es aromático, en donde el sistema bicíclico fusionado se sustituye opcionalmente con 1 a 5 grupos seleccionados independientemente de ORa, Hal, fenilo y alquilo C1-C6 en donde 1 a 5 átomos de H pueden reemplazarse independientemente por OH o Hal; o Q2 es un sistema de anillo de 5 miembros aromático que contiene 1 a 3 heteroátomos seleccionados de N, O, S y CO, y opcionalmente sustituido con un anillo fenilo o anillo de piridina, en donde el anillo fenilo y el anillo de piridina se sustituyen opcionalmente con 1 a 4 grupos seleccionados independientemente de ORa, Hal, fenilo y alquilo C1-C6, en donde 1 a 5 átomos de H pueden reemplazarse independientemente por OH o Hal; M es un alquileno lineal o ramificado que tiene 1 a 5 átomos de carbono, en donde 1 ó 2 átomos de H pueden reemplazarse por ORa o un anillo fenilo opcionalmente sustituido con 1 a 5 grupos seleccionados independientemente de Hal, ORa y alquilo C1-C6 opcionalmente sustituido con 1 a 5 grupos seleccionados independientemente de OH y Hal; o M representa un cicloalquileno que tiene 3 a 7 átomos de carbono; o M representa un grupo tiazolidinilo; Ra es un alquilo C1-C6 en donde 1 a 5 átomos de H pueden reemplazarse independientemente por OH o Hal; Ar representa un anillo carbocíclico aromático de 6 miembros fusionado opcionalmente con otro anillo carbocíclico saturado, insaturado o aromático que tiene 5 a 8 átomos de carbono; Het representa un anillo heterocíclico saturado, insaturado o aromático de 6 miembros que tiene 1 a 3 heteroátomos seleccionados independientemente de N, N+O-, O, S, SO y SO2, y opcionalmente fusionado con otro anillo saturado, insaturado o aromático que tiene 5 a 8 átomos y que contiene opcionalmente 1 a 3 heteroátomos seleccionados de N, O y S; Hal representa C1, Br, I o F; de preferencia C1 o F.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579076P | 2011-12-22 | 2011-12-22 | |
EP11195107 | 2011-12-22 | ||
PCT/EP2012/076595 WO2013092979A1 (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014007362A MX2014007362A (es) | 2014-08-01 |
MX352652B true MX352652B (es) | 2017-12-04 |
Family
ID=48667763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014007362A MX352652B (es) | 2011-12-22 | 2012-12-21 | Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9688702B2 (es) |
EP (1) | EP2793900B1 (es) |
JP (1) | JP6129203B2 (es) |
KR (1) | KR20140114391A (es) |
CN (1) | CN104321060B (es) |
AU (1) | AU2012356890B2 (es) |
BR (1) | BR112014015363A8 (es) |
CA (1) | CA2860142C (es) |
EA (1) | EA201400735A1 (es) |
ES (1) | ES2699267T3 (es) |
HK (1) | HK1206261A1 (es) |
IL (1) | IL233200A (es) |
MX (1) | MX352652B (es) |
SG (2) | SG11201403254QA (es) |
WO (1) | WO2013092979A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2603514T (pt) | 2010-08-10 | 2018-11-09 | Rempex Pharmaceuticals Inc | Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas |
WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
EP2925765B1 (en) | 2012-12-03 | 2016-12-14 | F. Hoffmann-La Roche AG | Substituted triazole boronic acid compounds |
PT2928898T (pt) | 2012-12-07 | 2021-07-05 | Venatorx Pharmaceuticals Inc | Inibidores de beta-lactamase |
CA2894891A1 (en) * | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CA2894892A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
USRE49816E1 (en) | 2014-01-10 | 2024-01-30 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
DK3140310T3 (da) | 2014-05-05 | 2019-10-21 | Rempex Pharmaceuticals Inc | Syntese af boronatsalte og brug deraf |
CA2947041A1 (en) | 2014-05-19 | 2015-11-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP3882252A1 (en) * | 2014-06-11 | 2021-09-22 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
EP3164406A4 (en) | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
BR112017006349A2 (pt) | 2014-10-01 | 2017-12-12 | Merck Patent Gmbh | derivados de ácido borônico |
BR112017006368A2 (pt) * | 2014-10-01 | 2017-12-19 | Merck Patent Gmbh | derivados de ácido borônico |
EP3201207B1 (en) * | 2014-10-01 | 2021-02-24 | Merck Patent GmbH | Boronic acid derivatives |
EP3201206B1 (en) | 2014-10-01 | 2019-09-18 | Merck Patent GmbH | Boronic acid derivatives |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
WO2017066763A1 (en) | 2015-10-15 | 2017-04-20 | Cornell University | Proteasome inhibitors and uses thereof |
WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CN107151255A (zh) * | 2016-03-06 | 2017-09-12 | 复旦大学 | 硼酸类化合物及其制备方法和用途 |
WO2018005662A1 (en) | 2016-06-30 | 2018-01-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
JP7189203B2 (ja) | 2017-08-24 | 2022-12-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ボロン酸誘導体 |
WO2019075084A1 (en) | 2017-10-11 | 2019-04-18 | Qpex Biopharma, Inc. | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF |
US11203613B2 (en) | 2017-10-11 | 2021-12-21 | Cornell University | Peptidomimetic proteasome inhibitors |
CN107556336A (zh) * | 2017-10-16 | 2018-01-09 | 康化(上海)新药研发有限公司 | 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法 |
SG11202003867SA (en) | 2017-11-16 | 2020-05-28 | Principia Biopharma Inc | Immunoproteasome inhibitors |
CN108130370B (zh) * | 2018-01-05 | 2020-11-17 | 武汉惠康达科技有限公司 | Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用 |
WO2020020858A1 (en) | 2018-07-26 | 2020-01-30 | Merck Patent Gmbh | Boronic acid derivatives |
CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
CN114075227B (zh) * | 2020-08-19 | 2023-07-04 | 北京嵩润医药科技有限责任公司 | 吡唑硼酸类化合物、包含其的药物组合物及它们的用途 |
IL310390A (en) | 2021-07-29 | 2024-03-01 | Merck Patent Gmbh | Crystalline forms of [(R1)-2-benzofuran-3-yl)-1-{[(R4, R2, S1)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, Their adducts and their use |
WO2023061445A1 (zh) * | 2021-10-14 | 2023-04-20 | 首药控股(北京)股份有限公司 | 硼酸衍生物 |
WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
US7271186B1 (en) * | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
US7332343B2 (en) * | 2004-01-16 | 2008-02-19 | Board Of Regents, The University Of Texas System | Determining enantiomeric excess using indicator-displacement assays |
DK2377869T3 (da) | 2004-03-30 | 2014-04-14 | Millennium Pharm Inc | Syntese af Bortezomib |
WO2008060488A1 (en) | 2006-11-14 | 2008-05-22 | Merck & Co., Inc. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
UA97536C2 (en) * | 2007-08-06 | 2012-02-27 | Милленниум Фармасьютикалз, Инк. | Proteasome inhibitors |
WO2009051581A1 (en) * | 2007-10-16 | 2009-04-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
JP2011503181A (ja) * | 2007-11-13 | 2011-01-27 | プロテズ・ファーマシューティカルズ・インコーポレイテッド | ベータ−ラクタマーゼ阻害剤 |
AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
KR20130036228A (ko) | 2010-03-31 | 2013-04-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 1-아미노-2-사이클로프로필에틸보론산의 유도체 |
US8507494B2 (en) | 2010-04-30 | 2013-08-13 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived M1 receptor positive allosteric modulators |
-
2012
- 2012-12-21 BR BR112014015363A patent/BR112014015363A8/pt not_active Application Discontinuation
- 2012-12-21 CA CA2860142A patent/CA2860142C/en active Active
- 2012-12-21 WO PCT/EP2012/076595 patent/WO2013092979A1/en active Application Filing
- 2012-12-21 MX MX2014007362A patent/MX352652B/es active IP Right Grant
- 2012-12-21 ES ES12806491T patent/ES2699267T3/es active Active
- 2012-12-21 SG SG11201403254QA patent/SG11201403254QA/en unknown
- 2012-12-21 US US14/366,949 patent/US9688702B2/en active Active
- 2012-12-21 AU AU2012356890A patent/AU2012356890B2/en active Active
- 2012-12-21 CN CN201280063440.0A patent/CN104321060B/zh active Active
- 2012-12-21 JP JP2014548061A patent/JP6129203B2/ja active Active
- 2012-12-21 SG SG10201605152SA patent/SG10201605152SA/en unknown
- 2012-12-21 EA EA201400735A patent/EA201400735A1/ru unknown
- 2012-12-21 KR KR1020147020413A patent/KR20140114391A/ko not_active Application Discontinuation
- 2012-12-21 EP EP12806491.2A patent/EP2793900B1/en active Active
-
2014
- 2014-06-17 IL IL233200A patent/IL233200A/en active IP Right Grant
-
2015
- 2015-07-21 HK HK15106906.3A patent/HK1206261A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL233200A (en) | 2017-08-31 |
WO2013092979A1 (en) | 2013-06-27 |
CN104321060A (zh) | 2015-01-28 |
CA2860142C (en) | 2020-10-27 |
CA2860142A1 (en) | 2013-06-27 |
KR20140114391A (ko) | 2014-09-26 |
IL233200A0 (en) | 2014-07-31 |
HK1206261A1 (en) | 2016-01-08 |
SG11201403254QA (en) | 2014-07-30 |
MX2014007362A (es) | 2014-08-01 |
ES2699267T3 (es) | 2019-02-08 |
EP2793900B1 (en) | 2018-08-22 |
AU2012356890A1 (en) | 2014-08-07 |
BR112014015363A2 (pt) | 2017-06-13 |
US9688702B2 (en) | 2017-06-27 |
EA201400735A1 (ru) | 2015-04-30 |
JP6129203B2 (ja) | 2017-05-17 |
CN104321060B (zh) | 2018-08-07 |
BR112014015363A8 (pt) | 2017-06-13 |
JP2015502387A (ja) | 2015-01-22 |
US20140364396A1 (en) | 2014-12-11 |
AU2012356890B2 (en) | 2017-06-08 |
SG10201605152SA (en) | 2016-08-30 |
EP2793900A1 (en) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014007362A (es) | Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico. | |
AR095347A1 (es) | Compuestos orgánicos | |
CY1117374T1 (el) | Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
MX2022008434A (es) | Herbicidas de piridazinona. | |
AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
IN2014DN03063A (es) | ||
EA201591000A1 (ru) | Пирролобензодиазепины | |
AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
EA201071112A1 (ru) | ПРОИЗВОДНЫЕ ПОЛИЗАМЕЩЁННЫХ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ИХ В ТЕРАПИИ | |
MX352928B (es) | Compuestos de piridazina-amida. | |
NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
EA201890094A1 (ru) | Производные полициклических амидов в качестве ингибиторов cdk9 | |
TN2012000609A1 (en) | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | |
EA201690135A1 (ru) | Трициклические соединения бензоксаборола и их применение | |
CY1112679T1 (el) | Κινολινες και θεραπευτικη χρηση αυτων | |
MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
EA201001087A1 (ru) | Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
PH12015502851B1 (en) | Curable composition | |
EA201590315A1 (ru) | Средства и способ лечения солидных опухолей | |
CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
MX2013010962A (es) | Nuevos derivados de furanona. | |
AR083832A1 (es) | DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS | |
NZ735032A (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
PE20081376A1 (es) | Derivados de pirrolizina, indolizina y quinolizina, su preparacion y su aplicacion en terapeutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |